What two-part therapy for Type 1 diabetes, involving lab-made insulin-producing cells and engineered immune cells, was announced in March 2026?

A significant advancement in the treatment of Type 1 diabetes, announced in March 2026, involves a novel approach known as cellular therapy. This innovative two-part therapy aims to address the root cause of Type 1 diabetes, which is the immune system's destruction of insulin-producing beta cells in the pancreas. The breakthrough combines two distinct cellular components to not only restore insulin production but also protect these new cells from immune attack.

The first part of this therapy utilizes lab-made insulin-producing cells, which are designed to replace the beta cells lost in individuals with Type 1 diabetes. These cells are crucial for regulating blood sugar levels by producing insulin. The second, equally vital component involves custom-engineered immune cells. These specialized immune cells act as "bodyguards," trained to protect the transplanted insulin-producing cells from the patient's own immune system, thereby preventing rejection without the need for broad immunosuppressive drugs. The Medical University of South Carolina (MUSC) announced this two-part strategy, which seeks to eliminate the significant long-term risks associated with traditional immunosuppressants, especially for children.

This cellular therapy represents a bold step towards a potential cure for Type 1 diabetes. By pairing the restorative power of lab-grown beta cells with the protective capabilities of engineered immune cells, researchers hope to create a ready-to-use, off-the-shelf treatment that could free people from daily insulin injections. The approach is designed to be scalable, overcoming the current shortage of donor tissue often required for traditional islet cell transplants. With ongoing research and funding from organizations like Breakthrough T1D, this therapy holds immense promise for transforming the lives of millions affected by Type 1 diabetes, even those who have lived with the disease for many years.